<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="alz14537" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1552-5279</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &#x00026; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40008832</article-id><article-id pub-id-type="pmc">PMC11863240</article-id><article-id pub-id-type="doi">10.1002/alz.14537</article-id><article-id pub-id-type="publisher-id">ALZ14537</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Plasma p&#x02010;tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10&#x02010;year window</article-title><alt-title alt-title-type="left-running-head">YAKOUB <sc>et&#x000a0;al.</sc>
</alt-title></title-group><contrib-group><contrib id="alz14537-cr-0001" contrib-type="author"><name><surname>Yakoub</surname><given-names>Yara</given-names></name><xref rid="alz14537-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz14537-cr-0002" contrib-type="author"><name><surname>Gonzalez&#x02010;Ortiz</surname><given-names>Fernando</given-names></name><xref rid="alz14537-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz14537-cr-0003" contrib-type="author"><name><surname>Ashton</surname><given-names>Nicholas J.</given-names></name><xref rid="alz14537-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz14537-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz14537-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="alz14537-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz14537-cr-0004" contrib-type="author"><name><surname>D&#x000e9;ry</surname><given-names>Christine</given-names></name><xref rid="alz14537-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz14537-cr-0005" contrib-type="author"><name><surname>Strikwerda&#x02010;Brown</surname><given-names>Cherie</given-names></name><xref rid="alz14537-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz14537-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="alz14537-cr-0006" contrib-type="author"><name><surname>St&#x02010;Onge</surname><given-names>Fr&#x000e9;d&#x000e9;ric</given-names></name><xref rid="alz14537-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz14537-cr-0007" contrib-type="author"><name><surname>Ourry</surname><given-names>Valentin</given-names></name><xref rid="alz14537-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz14537-cr-0008" contrib-type="author"><name><surname>Sch&#x000f6;ll</surname><given-names>Michael</given-names></name><xref rid="alz14537-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz14537-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz14537-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="alz14537-cr-0009" contrib-type="author"><name><surname>Geddes</surname><given-names>Maiya R.</given-names></name><xref rid="alz14537-aff-0008" ref-type="aff">
<sup>8</sup>
</xref><xref rid="alz14537-aff-0009" ref-type="aff">
<sup>9</sup>
</xref><xref rid="alz14537-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="alz14537-cr-0010" contrib-type="author"><name><surname>Ducharme</surname><given-names>Simon</given-names></name><xref rid="alz14537-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz14537-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="alz14537-cr-0011" contrib-type="author"><name><surname>Montembeault</surname><given-names>Maxime</given-names></name><xref rid="alz14537-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz14537-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="alz14537-cr-0012" contrib-type="author"><name><surname>Rosa&#x02010;Neto</surname><given-names>Pedro</given-names></name><xref rid="alz14537-aff-0008" ref-type="aff">
<sup>8</sup>
</xref><xref rid="alz14537-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="alz14537-cr-0013" contrib-type="author"><name><surname>Soucy</surname><given-names>Jean&#x02010;Paul</given-names></name><xref rid="alz14537-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="alz14537-cr-0014" contrib-type="author"><name><surname>Breitner</surname><given-names>John C. S.</given-names></name><xref rid="alz14537-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz14537-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="alz14537-cr-0015" contrib-type="author"><name><surname>Zetterberg</surname><given-names>Henrik</given-names></name><xref rid="alz14537-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz14537-aff-0007" ref-type="aff">
<sup>7</sup>
</xref><xref rid="alz14537-aff-0012" ref-type="aff">
<sup>12</sup>
</xref><xref rid="alz14537-aff-0013" ref-type="aff">
<sup>13</sup>
</xref><xref rid="alz14537-aff-0014" ref-type="aff">
<sup>14</sup>
</xref><xref rid="alz14537-aff-0015" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib id="alz14537-cr-0016" contrib-type="author"><name><surname>Blennow</surname><given-names>Kaj</given-names></name><xref rid="alz14537-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz14537-aff-0012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib id="alz14537-cr-0017" contrib-type="author"><name><surname>Poirier</surname><given-names>Judes</given-names></name><xref rid="alz14537-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz14537-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="alz14537-cr-0018" contrib-type="author" corresp="yes"><name><surname>Villeneuve</surname><given-names>Sylvia</given-names></name><xref rid="alz14537-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz14537-aff-0008" ref-type="aff">
<sup>8</sup>
</xref><xref rid="alz14537-aff-0011" ref-type="aff">
<sup>11</sup>
</xref><address><email>Sylvia.villeneuve@mcgill.ca</email></address></contrib><contrib id="alz14537-cr-0019" contrib-type="author"><collab collab-type="authors">PREVENT&#x02212;AD Research Group</collab></contrib></contrib-group><aff id="alz14537-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Douglas Mental Health University Institute</named-content>
<institution>Centre for Studies on the Prevention of Alzheimer's Disease (StoP&#x02010;AD)</institution>
<city>Montreal</city>
<named-content content-type="country-part">Quebec</named-content>
<country country="CA">Canada</country>
</aff><aff id="alz14537-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry and Neurochemistry</named-content>
<named-content content-type="organisation-division">Institute of Neuroscience and Physiology</named-content>
<institution>The Sahlgrenska Academy, University of Gothenburg</institution>
<city>Gothenburg</city>
<country country="SE">Sweden</country>
</aff><aff id="alz14537-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Centre for Age&#x02010;Related Medicine</named-content>
<institution>Stavanger University Hospital</institution>
<city>Stavanger</city>
<country country="NO">Norway</country>
</aff><aff id="alz14537-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">King's College London</named-content>
<named-content content-type="organisation-division">Institute of Psychiatry, Psychology &#x00026; Neuroscience</named-content>
<institution>Maurice Wohl Clinical Neuroscience Institute</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><aff id="alz14537-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>Banner Alzheimer's Institute</institution>
<city>Phoenix</city>
<named-content content-type="country-part">Arizona</named-content>
<country country="US">USA</country>
</aff><aff id="alz14537-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">School of Psychological Sciences</named-content>
<institution>The University of Western Australia</institution>
<city>Perth</city>
<named-content content-type="country-part">Western Australia</named-content>
<country country="AU">Australia</country>
</aff><aff id="alz14537-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Neurodegenerative Disease</named-content>
<named-content content-type="organisation-division">UCL Queen Square Institute of Neurology</named-content>
<institution>University College London</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><aff id="alz14537-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Montreal Neurological Institute</named-content>
<institution>McGill University</institution>
<city>Montreal</city>
<named-content content-type="country-part">Quebec</named-content>
<country country="CA">Canada</country>
</aff><aff id="alz14537-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">McGovern Institute for Brain Research</named-content>
<institution>Massachusetts Institute of Technology</institution>
<city>Cambridge</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz14537-aff-0010">
<label>
<sup>10</sup>
</label>
<institution>McGill University Research Centre for Studies in Aging, McGill University</institution>
<city>Montreal</city>
<named-content content-type="country-part">Quebec</named-content>
<country country="CA">Canada</country>
</aff><aff id="alz14537-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>McGill University</institution>
<city>Montreal</city>
<named-content content-type="country-part">Quebec</named-content>
<country country="CA">Canada</country>
</aff><aff id="alz14537-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Clinical Neurochemistry Laboratory</named-content>
<institution>Sahlgrenska University Hospital</institution>
<city>M&#x000f6;lndal</city>
<country country="SE">Sweden</country>
</aff><aff id="alz14537-aff-0013">
<label>
<sup>13</sup>
</label>
<institution>UK Dementia Research Institute at UCL</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><aff id="alz14537-aff-0014">
<label>
<sup>14</sup>
</label>
<institution>Hong Kong Center for Neurodegenerative Diseases</institution>
<city>Hong Kong</city>
<country country="HK">Hong Kong</country>
</aff><aff id="alz14537-aff-0015">
<label>
<sup>15</sup>
</label>
<named-content content-type="organisation-division">UW Department of Medicine</named-content>
<institution>School of Medicine and Public Health</institution>
<city>Madison</city>
<named-content content-type="country-part">Wisconsin</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Sylvia Villeneuve, Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer's Disease (StoP&#x02010;AD), Perry Pavilion Room E3417.1, 6875 Boulevard LaSalle, Montreal, QC H4H1R3, Canada.<break/> Email: <email>Sylvia.villeneuve@mcgill.ca</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>21</volume><issue seq="1900">2</issue><issue-id pub-id-type="doi">10.1002/alz.v21.2</issue-id><elocation-id>e14537</elocation-id><history>
<date date-type="rev-recd"><day>12</day><month>12</month><year>2024</year></date>
<date date-type="received"><day>08</day><month>10</month><year>2024</year></date>
<date date-type="accepted"><day>18</day><month>12</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 the Alzheimer's Association.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Alzheimer's &#x00026; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:ALZ-21-e14537.pdf"/><abstract><title>Abstract</title><sec id="alz14537-sec-0010"><title>INTRODUCTION</title><p>We assessed the prognostic accuracy of plasma p&#x02010;tau217 in predicting the progression to mild cognitive impairment (MCI) in cognitively unimpaired (CU) individuals over a mean follow&#x02010;up of 5.65 years after plasma collection (range 1.01&#x02013;10.47).</p></sec><sec id="alz14537-sec-0020"><title>METHODS</title><p>We included 215 participants from the PREVENT&#x02212;AD cohort with plasma A&#x003b2;<sub>42/40</sub> and p&#x02010;tau217, 159 with cerebrospinal fluid (CSF) A&#x003b2;<sub>42/40</sub> and p&#x02010;tau217, and 155 with <sup>18</sup>F&#x02010;NAV4694 and <sup>18</sup>F&#x02010;flortaucipir PET scans. MCI progression was determined by multidisciplinary consensus among memory experts blind to biomarker and genetic information.</p></sec><sec id="alz14537-sec-0030"><title>RESULTS</title><p>Cox proportional hazard models indicated a greater progression rate in A+T+<sub>plasma</sub> and A&#x02212;T+<sub>plasma</sub> compared to A&#x02212;T&#x02212;<sub>plasma</sub> individuals (HR&#x000a0;=&#x000a0;7.81 [95% CI&#x000a0;=&#x000a0;3.92 to 15.59] and HR&#x000a0;=&#x000a0;4.25 [1.60&#x02013;11.31] respectively). Similar results were found with CSF (HR&#x000a0;=&#x000a0;3.63 [1.72&#x02013;7.70]) and PET (HR&#x000a0;=&#x000a0;9.30 [3.67&#x02013;23.55]).</p></sec><sec id="alz14537-sec-0040"><title>DISCUSSION</title><p>Plasma p&#x02010;tau217 is a prognostic marker for identifying individuals who will develop cognitive impairment within ten years.</p></sec><sec id="alz14537-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz14537-list-0001"><list-item><p>Elevated plasma p&#x02010;tau217 levels in CU individuals indicate future clinical progression.</p></list-item><list-item><p>Adding plasma A&#x003b2;<sub>42/40</sub> status to p&#x02010;tau markers did not improve the prediction to MCI.</p></list-item><list-item><p>All individuals with abnormal tau PET measured in a temporal meta&#x02010;ROI progressed to MCI.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz14537-kwd-0001">amyloid</kwd><kwd id="alz14537-kwd-0002">CSF</kwd><kwd id="alz14537-kwd-0003">MCI</kwd><kwd id="alz14537-kwd-0004">PET</kwd><kwd id="alz14537-kwd-0005">plasma</kwd><kwd id="alz14537-kwd-0006">tau</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Sahlgrenska Academy at the University of Gothenburg</funding-source></award-group><award-group id="funding-0002"><funding-source>the Alzheimerfonden</funding-source><award-id>AF&#x02010;994900</award-id></award-group><award-group id="funding-0003"><funding-source>the National Institute of Health</funding-source><award-id>R01AG081394&#x02010;01</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Knut och Alice Wallenbergs Stiftelse
</institution><institution-id institution-id-type="doi">10.13039/501100004063</institution-id></institution-wrap></funding-source><award-id>KAW2014.0363</award-id><award-id>KAW 2023.0371</award-id></award-group><award-group id="funding-0005"><funding-source>Biogen Canada</funding-source></award-group><award-group id="funding-0006"><funding-source><institution-wrap><institution>Natural Sciences and Engineering Research Council of Canada
</institution><institution-id institution-id-type="doi">10.13039/501100000038</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0007"><funding-source>the Fonds de recherche du Qu&#x000e9;bec</funding-source></award-group><award-group id="funding-0008"><funding-source><institution-wrap><institution>Fondation Jean&#x02010;Louis L&#x000e9;vesque
</institution><institution-id institution-id-type="doi">10.13039/100013367</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0009"><funding-source>National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre</funding-source></award-group><award-group id="funding-0010"><funding-source>European Union Joint Programme &#x02013; Neurodegenerative Disease Research</funding-source><award-id>JPND2021&#x02010;00694</award-id></award-group><award-group id="funding-0011"><funding-source>European Union's Horizon 2020 research and innovation programme under the Marie Sk&#x00142;odowska&#x02212;Curie grant agreement</funding-source><award-id>860197</award-id></award-group><award-group id="funding-0012"><funding-source><institution-wrap><institution>Alzheimer's Association
</institution><institution-id institution-id-type="doi">10.13039/100000957</institution-id></institution-wrap></funding-source><award-id>#ADSF&#x02010;21&#x02010;831376&#x02010;C</award-id><award-id>#ADSF&#x02010;21&#x02010;831381&#x02010;C</award-id><award-id>#ADSF&#x02010;21&#x02010;831377&#x02010;C</award-id><award-id>and #ADSF&#x02010;24&#x02010;1284328&#x02010;C</award-id></award-group><award-group id="funding-0013"><funding-source><institution-wrap><institution>Alzheimer's Drug Discovery Foundation
</institution><institution-id institution-id-type="doi">10.13039/100002565</institution-id></institution-wrap></funding-source><award-id>#201809&#x02010;2016862</award-id></award-group><award-group id="funding-0014"><funding-source>Swedish State Support for Clinical Research</funding-source><award-id>#ALFGBG&#x02010;71320</award-id><award-id>#ALFGBG813971</award-id><award-id>#ALFGBG&#x02010;965326</award-id></award-group><award-group id="funding-0015"><funding-source><institution-wrap><institution>HORIZON EUROPE Reforming and enhancing the European Research and Innovation system
</institution><institution-id institution-id-type="doi">10.13039/100018707</institution-id></institution-wrap></funding-source><award-id>101132933</award-id><award-id>101112145</award-id></award-group><award-group id="funding-0016"><funding-source><institution-wrap><institution>Swedish Research Council
</institution><institution-id institution-id-type="doi">10.13039/501100004359</institution-id></institution-wrap></funding-source><award-id>#2017&#x02010;02869</award-id><award-id>#2021&#x02010;02678</award-id><award-id>#2021&#x02010;06545</award-id><award-id>#2023&#x02010;06188</award-id></award-group><award-group id="funding-0017"><funding-source>the Canadian Institutes of Health Research</funding-source></award-group><award-group id="funding-0018"><funding-source><institution-wrap><institution>Fondation Brain Canada
</institution><institution-id institution-id-type="doi">10.13039/100009408</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0019"><funding-source>UK Dementia Research Institute at UCL</funding-source><award-id>UKDRI&#x02010;1003</award-id></award-group><award-group id="funding-0020"><funding-source>V&#x000e4;stra G&#x000f6;taland Region R&#x00026;D</funding-source><award-id>VGFOUREG&#x02010;995510</award-id></award-group><award-group id="funding-0021"><funding-source>Bluefield Project</funding-source></award-group><award-group id="funding-0022"><funding-source>the Cure Alzheimer's Fund</funding-source></award-group><award-group id="funding-0023"><funding-source>Erling&#x02010;Persson Family Foundation</funding-source></award-group><award-group id="funding-0024"><funding-source>Familjen R&#x000f6;nstr&#x000f6;ms Stiftelse</funding-source></award-group><award-group id="funding-0025"><funding-source>the Stiftelsen f&#x000f6;r Gamla Tj&#x000e4;narinnor</funding-source></award-group><award-group id="funding-0026"><funding-source>the Hj&#x000e4;rnfonden</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="1"/><page-count count="12"/><word-count count="7988"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:26.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz14537-cit-0041">
<string-name>
<surname>Yakoub</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Gonzalez&#x02010;Ortiz</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ashton</surname>
<given-names>NJ</given-names>
</string-name>, et&#x000a0;al. <article-title>Plasma p&#x02010;tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10&#x02010;year window</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1002/alz.14537</pub-id>
</mixed-citation>
</p></notes></front><body><sec id="alz14537-sec-0060"><label>1</label><title>BACKGROUND</title><p>The core pathological hallmarks that define Alzheimer's disease (AD) are plaque&#x02010;forming aggregates of amyloid beta (A&#x003b2;) and neurofibrillary tangles of hyper&#x02010;phosphorylated tau (p&#x02010;tau). These proteins start to accumulate up to 20 years before the disease's clinical onset.<xref rid="alz14537-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> They can be measured in vivo using positron emission tomography (PET); cerebrospinal fluid (CSF) assays; and more recently, blood&#x02010;based biomarkers.<xref rid="alz14537-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz14537-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
</p><p>PET and CSF biomarkers of A&#x003b2; and tau have been largely validated and can now be used to support AD diagnosis and to enroll AD patients in clinical trials. More recently, A&#x003b2; and tau PET have shown value in identifying cognitively unimpaired (CU) individuals at imminent risk (3&#x02013;5 years) of developing mild cognitive impairment (MCI).<xref rid="alz14537-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz14537-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> With the emergence of disease&#x02010;modifying therapies, it has become urgent to find low&#x02010;cost and widely available biomarkers that can identify CU individuals who will develop cognitive impairments. Prognostic information is therefore of critical value for informing treatment decisions, balancing risk/benefit, and establishing advance directives.</p><p>The field of plasma biomarkers has evolved dramatically over the past 5 years, with p&#x02010;tau217 plasma biomarkers emerging as one of the most promising at identifying individuals with AD pathology.<xref rid="alz14537-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> However, imaging and fluid biomarkers of A&#x003b2; and tau reflect different biochemical pools of proteins; fluid biomarkers capture soluble and diffusible proteins, whereas PET images capture insoluble aggregates that are characteristic of the later stages of the disease.<xref rid="alz14537-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Consequently, it is hypothesized that A&#x003b2; and tau fluid biomarker abnormalities occur prior to PET abnormalities,<xref rid="alz14537-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="alz14537-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="alz14537-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> and that PET abnormalities are more closely related to the development of cognitive impairments. Therefore, plasma p&#x02010;tau217 may not have the same prognostic value as tau PET in identifying CU individuals who will develop MCI.</p><p>In a longitudinal study spanning &#x0003e; 10 years, we assessed the prognostic value of novel plasma p&#x02010;tau217 assays in predicting progression from CU to MCI. The prognostic value of plasma markers was then compared to the prognostic value of CSF p&#x02010;tau217 and PET biomarkers. MCI classification was performed blind to genetic and pathological biomarkers.</p></sec><sec id="alz14537-sec-0070"><label>2</label><title>METHODS</title><p>We included 215 participants from the Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT&#x02010;AD) cohort, a longitudinal observational study of individuals with a first&#x02010;degree family history of AD (Figure <xref rid="alz14537-supinfo-0001" ref-type="">S1</xref> in supporting information). Longitudinal data collected between 2011 and 2023 and available plasma (A&#x003b2;<sub>42/40</sub> and p&#x02010;tau217) biomarkers, 159 participants with available CSF p&#x02010;tau217 and A&#x003b2;<sub>42/40</sub> values, and 155 with both A&#x003b2; and tau PET available (Methods S1 in supporting information). Plasma and CSF measurements were collected from the beginning of the study while PET measurements started in 2017. Plasma and CSF time points closest to the PET scans were selected for this study (<xref rid="alz14537-supinfo-0001" ref-type="">see Methods</xref> S1 and Figure <xref rid="alz14537-supinfo-0001" ref-type="">S2</xref> in supporting information). For individuals who did not have PET scans, the plasma sample closest to 2017 was taken. Plasma, CSF, and PET biomarkers were not necessarily collected on the same day. Participants included in this study were CU based on an extensive neuropsychological evaluation at the time of the biomarker assessment and had a minimum of 1 year of cognitive follow&#x02010;up thereafter. To ease comparison among biomarkers, a subsample of 93 participants with all biomarker modalities were included in a supplementary analysis. The demographic and clinical information of plasma, CSF, and PET full samples can be found in Table&#x000a0;<xref rid="alz14537-tbl-0001" ref-type="table">1</xref>. The characteristics of the corresponding AT groups in plasma, CSF, and PET can be found in Tables <xref rid="alz14537-supinfo-0001" ref-type="">S1&#x02013;S3</xref> in supporting information. The amyloid/tau (AT) group demographic characteristics of the subsample of 93 participants with all biomarkers can be found in Tables <xref rid="alz14537-supinfo-0001" ref-type="">S4&#x02013;S6</xref> in supporting information. Written informed consent was obtained from all participants, and all research procedures were approved by the institutional review board at McGill University and complied with the ethical principles of the Declaration of Helsinki. A detailed description of the PREVENT&#x02010;AD cohort is available elsewhere.<xref rid="alz14537-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p><table-wrap position="float" id="alz14537-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Sample demographics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Demographics</th><th align="left" rowspan="1" colspan="1">Plasma (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;215)</th><th align="left" rowspan="1" colspan="1">CSF (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;159)</th><th align="left" rowspan="1" colspan="1">PET (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;155)</th><th align="left" rowspan="1" colspan="1">Group differences</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Age at baseline, years</bold>
</td><td align="char" rowspan="1" colspan="1">63.19 (4.85)</td><td align="char" rowspan="1" colspan="1">62.92 (4.80)</td><td align="char" rowspan="1" colspan="1">63.70 (4.62)</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age at biomarker classification, years</bold>
<xref rid="alz14537-tbl1-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">65.16 (5.28)</td><td align="char" rowspan="1" colspan="1">64.75 (5.26)</td><td align="char" rowspan="1" colspan="1">67.64 (5.01)</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001<xref rid="alz14537-tbl1-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>, <xref rid="alz14537-tbl1-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Sex, <italic toggle="yes">F</italic> (%)</bold>
</td><td align="char" rowspan="1" colspan="1">157 (73)</td><td align="char" rowspan="1" colspan="1">113 (71)</td><td align="char" rowspan="1" colspan="1">111 (72)</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Education, years</bold>
</td><td align="char" rowspan="1" colspan="1">15.29 (3.25)</td><td align="char" rowspan="1" colspan="1">15.14 (3.17)</td><td align="char" rowspan="1" colspan="1">15.33 (3.25)</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">APOE</italic> &#x003b5;4 carriers, <italic toggle="yes">n</italic> (%)</bold>
</td><td align="char" rowspan="1" colspan="1">88 (41)</td><td align="char" rowspan="1" colspan="1">62 (39)</td><td align="char" rowspan="1" colspan="1">62 (40)</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.96</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Global amyloid SUVR</bold>
</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="char" rowspan="1" colspan="1">1.31(0.30)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Temporal meta&#x02010;ROI SUVR</bold>
</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="char" rowspan="1" colspan="1">1.16 (0.11)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>A&#x003b2;<sub>42/40</sub>
</bold>
</td><td align="char" rowspan="1" colspan="1">0.09 (0.01)</td><td align="char" rowspan="1" colspan="1">0.09 (0.02)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>p&#x02010;tau217</bold>
<bold>(pg/ml)</bold>
</td><td align="char" rowspan="1" colspan="1">2.63 (1.56)</td><td align="char" rowspan="1" colspan="1">251.70 (173.65)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MoCA score/30</bold>
</td><td align="char" rowspan="1" colspan="1">28.11 (1.57)</td><td align="char" rowspan="1" colspan="1">28.05 (1.58)</td><td align="char" rowspan="1" colspan="1">28.14 (1.51)</td><td align="left" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>RBANS global score</bold>
</td><td align="char" rowspan="1" colspan="1">101.57 (9.85)</td><td align="char" rowspan="1" colspan="1">101.10 (9.80)</td><td align="char" rowspan="1" colspan="1">102.54 (10.12)</td><td align="left" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MMSE score/30</bold>
</td><td align="char" rowspan="1" colspan="1">28.81 (1.24)</td><td align="char" rowspan="1" colspan="1">28.80 (1.27)</td><td align="char" rowspan="1" colspan="1">28.83 (1.25)</td><td align="left" rowspan="1" colspan="1">0.98</td></tr></tbody></table><table-wrap-foot><fn id="alz14537-tbl1-note-0001"><p>
<italic toggle="yes">Note</italic>: Represents the characteristics of plasma, CSF, and PET full sample and their corresponding AT groups. Data presented as mean (standard deviation), except for categorical variables where the count and percentage are presented. Fisher or Kruskal&#x02013;Wallis test was performed between the groups and <italic toggle="yes">P</italic> values are reported in the right column. If a significant group difference (<italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) was found post hoc tests are performed. Age at baseline and at biomarker measurement are presented; MoCA scores were collected at entry into the program; RBANS values are shown at baseline; MMSE scores selected closest to the biomarker measurement. MoCA score was missing for one participant in the plasma and CSF sample. MMSE scores were available for a subset of participants (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;188 for plasma sample, <italic toggle="yes">n</italic>&#x000a0;=&#x000a0;136 for CSF sample, and <italic toggle="yes">n</italic>&#x000a0;=&#x000a0;154 for PET sample). Abbreviations: <italic toggle="yes">APOE</italic>, apolipoprotein E; AT, amyloid/tau; CSF, cerebrospinal fluid; F, Female; MMSE, Mini&#x02010;Mental State Examination; MoCA, Montreal Cognitive Assessment; PET, positron emission tomography; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; SUVR, standardized uptake value ratio.</p></fn><fn id="alz14537-tbl1-note-0002"><label>
<sup>a</sup>
</label><p>Difference between plasma and PET.</p></fn><fn id="alz14537-tbl1-note-0003"><label>
<sup>b</sup>
</label><p>Difference between CSF and PET.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><sec id="alz14537-sec-0080"><label>2.1</label><title>Biomarker measurements and AT classification</title><p>Plasma and CSF p&#x02010;tau217 were measured using an in&#x02010;house Simoa platform developed at the Clinical Neurochemistry Laboratory, University of Gothenburg.<xref rid="alz14537-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Plasma A&#x003b2;<sub>40</sub> and A&#x003b2;<sub>42</sub> concentrations were measured using ultrasensitive immunoprecipitation coupled with mass spectrometry (IP&#x02010;MS) technique using a KingFisher Flex Purification System (Thermo Fisher Scientific) at the Clinical Neurochemistry Laboratory.<xref rid="alz14537-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> CSF A&#x003b2;<sub>40</sub> and A&#x003b2;<sub>42</sub> were analyzed using LUMIPULSE G&#x02010;automated immunoassay (Fujirebio, Ghent, Belgium).<xref rid="alz14537-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Tau PET scans were performed using <sup>18</sup>F&#x02010;flortaucipir and A&#x003b2; PET scans using <sup>18</sup>F&#x02010;NAV4694.<xref rid="alz14537-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><boxed-text position="float" content-type="box"><sec id="alz14537-sec-0090"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz14537-list-0002"><list-item><p>
<bold>Systematic review</bold>: We searched PubMed for plasma, CSF, and PET biomarkers of Alzheimer's disease (AD). Amyloid (A) and phosphorylated&#x02010;tau (p&#x02010;tau, T) blood biomarkers have been recently added to the revised criteria for diagnosis and staging of AD. There is limited evidence on whether plasma biomarkers can identify cognitively unimpaired (CU) who will develop mild cognitive impairment (MCI). In this prospective study, we evaluated the prognostic accuracy of amyloid and p&#x02010;tau plasma biomarkers in predicting MCI progression compared to CSF and PET biomarkers.</p></list-item><list-item><p>
<bold>Interpretation</bold>: Our study provided strong evidence on the prognostic utility of plasma p&#x02010;tau217 in predicting future clinical progression. Amyloid and tau positive individuals in plasma showed higher risk for future cognitive impairment, similar to PET and CSF. Interestingly, amyloid markers did not improve the predictivity of the tau markers, which can be explained by the fact that almost all T+ participants were also A+.</p></list-item><list-item><p>
<bold>Future directions</bold>: Future studies in diverse populations and community settings are needed to validate our findings.</p></list-item></list>
</p></sec></boxed-text><p>A&#x003b2; PET images using <sup>18</sup>F&#x02010;NAV4694 as tracer were captured 40 to 70&#x000a0;minutes after injecting a targeted dose of 220&#x000a0;MBq (6&#x000a0;mCi). Tau PET images using <sup>18</sup>F&#x02010;flortaucipir as tracer were obtained 80 to 100&#x000a0;minutes after injection with a targeted dose of 370&#x000a0;MBq (10&#x000a0;mCi). We acquired six frames of 5&#x000a0;minutes for NAV and four frames of 5&#x000a0;minutes for FTP. An in&#x02010;house pipeline (<ext-link xlink:href="https://github.com/villeneuvelab/vlpp" ext-link-type="uri">https://github.com/villeneuvelab/vlpp</ext-link>) was used for the preprocessing of all PET scans (see <xref rid="alz14537-supinfo-0001" ref-type="">supporting</xref> information for more details). For the main analyses, A&#x003b2; was quantified in a global index<xref rid="alz14537-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz14537-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> including temporal, parietal, and frontal regions of interest (ROIs), while tau was quantified in a temporal meta&#x02010;ROI (see <xref rid="alz14537-supinfo-0001" ref-type="">supporting</xref> information for more details).<xref rid="alz14537-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> The analyses were repeated when tau was solely quantified in the entorhinal cortex, a region with early tau accumulation.<xref rid="alz14537-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz14537-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p><p>For the binary analyses, plasma and CSF p&#x02010;tau217 levels were set at 2 standard deviation (SD) above the mean of A&#x003b2; PET&#x02013;negative individuals who were CU from the PREVENT&#x02010;AD cohort (plasma p&#x02010;tau217: 3.98&#x000a0;pg/mL; CSF p&#x02010;tau217: 400.19&#x000a0;pg/mL).<xref rid="alz14537-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> For tau positivity, we used a pre&#x02010;established threshold of 1.29 standardized uptake value ratio (SUVR) in a temporal meta&#x02010;ROI, that was also based on 2 SD above the mean of CU A&#x003b2; PET&#x02013;negative individuals from our cohort.<xref rid="alz14537-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Using the same method, the entorhinal tau PET threshold corresponded to a SUVR of 1.22. We used the pre&#x02010;established thresholds of 0.09 for plasma A&#x003b2;<sub>42/40</sub> and 0.072 for CSF A&#x003b2;<sub>42/40</sub>.<xref rid="alz14537-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz14537-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> A&#x003b2; PET positivity threshold was SUVR of 1.26 and was determined as the midpoint between the liberal and the conservative threshold.<xref rid="alz14537-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> The liberal threshold (SUVR 1.18) was calculated as 2 SD above the mean of 11 young individuals&#x000a0;(&#x0003c;&#x000a0;40 years old) who underwent the same PET protocol, while the conservative threshold (SUVR 1.33) was established using Gaussian mixture modeling. While we are using pre&#x02010;established methods to define our thresholds for the main analyses to increase generalizability of the findings, Tables <xref rid="alz14537-supinfo-0001" ref-type="">S7&#x02013;S12</xref> in supporting information further show the sensitivity, specificity, negative predictive value, and positive predictive value of all other possible thresholds, derived using progression status as the outcome variable.</p></sec><sec id="alz14537-sec-0100"><label>2.2</label><title>Outcomes</title><p>MCI classification was determined in a reserch setting based on a multidisciplinary consensus meeting comprising dementia specialist neuropsychologists (SV and MM) and physicians (SD and MG). Individuals with a cognitive performance deviating by more than 1.0 SD from demographically stratified norms on at least one of the five composite subscale scores (immediate memory, delayed memory, attention, visuospatial ability, and language) of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), or on two subset scores on the Rey Auditory Verbal Learning Test (RAVLT) were revised in consensus. When reviewed in consensus meeting, cognitive data at all available time points were examined. In addition to an objective impairment on the RBANS or the RAVLT, to be classified as MCI, participants needed to have a subjective memory complaint<xref rid="alz14537-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> and/or have an objective decline witnessed over multiple cognitive follow&#x02010;ups. All MCI classification was performed blind to plasma, CSF, PET, magnetic resonance imaging (MRI), and apolipoprotein E (<italic toggle="yes">APOE</italic>) genotype information.<xref rid="alz14537-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Most MCI participants were later evaluated in a clinical setting and the most recent available information related to the severity of the cognitive impairment is reported in&#x000a0;Figure <xref rid="alz14537-supinfo-0001" ref-type="">S3</xref> in supporting information. This information is not treated as a main outcome as it was obtained unblinded to <italic toggle="yes">APOE</italic> genotype and AD biomarker status.</p><p>In secondary analyses, we examined the longitudinal cognitive trajectories of individuals using the total composite score of the RBANS as an outcome. The RBANS is administered to PREVENT&#x02010;AD participants throughout the entire study follow&#x02010;up. These secondary analyses took advantage of all cognitive time points, including cognitive evaluations prior to and after the biomarker classification, except for virtual evaluations performed during the COVID&#x02010;19 pandemic.</p></sec><sec id="alz14537-sec-0110"><label>2.3</label><title>Statistical analyses</title><p>Demographic and clinical variables by biomarker and by AT classification were compared using Kruskal&#x02013;Wallis tests followed by a Dunn post hoc test for continuous variables and Fisher exact tests for categorical variables. Cox proportional hazard models were used to assess the risk of MCI progression by AT group and linear mixed models were used to assess longitudinal cognitive changes across the biomarker groups with the addition of age at the biomarker classification, sex, and years of education as covariates. We then tested the cognitive performance over time across the different biomarker groups using linear mixed&#x02010;effects models. Change in the age&#x02010;adjusted RBANS total score over time was used as an outcome variable with time and biomarker group as interaction terms, with a random slope and intercept for time per subject. Each model was adjusted for sex and education as potential confounders (e.g., [RBANS &#x0223c; time&#x000a0;&#x000d7;&#x000a0;AT biomarker group&#x000a0;+&#x000a0;sex&#x000a0;+&#x000a0;years of education&#x000a0;+&#x000a0;(time | subject)]) using the A&#x02212;T&#x02212; group as the reference group. Spearman rank test and Cohen kappa were used to evaluate the association between the biomarkers. Receiver operating characteristic (ROC) analyses were used to test the performance of plasma, CSF, and PET biomarkers as continuous variables in predicting the progression to MCI. The resulting areas under the curve (AUCs) were also computed to assess the biomarker accuracy in distinguishing between CU who remained CU during the study length versus those who progressed to MCI. These last analyses were done using A&#x003b2; and tau in separate models and when combined, to assess the additive value of having A&#x003b2; markers in addition to the tau biomarkers. Model fits were compared using a Vuong test. Two&#x02010;sided <italic toggle="yes">P</italic> values&#x000a0;&#x0003c;&#x000a0;0.05 were deemed significant. The analyses were performed using the R programming language.</p></sec></sec><sec id="alz14537-sec-0120"><label>3</label><title>RESULTS</title><sec id="alz14537-sec-0130"><label>3.1</label><title>Participants</title><p>A total of 228 participants were included in the study, of whom 62 (27%) developed MCI. Across all participants, the mean duration of cognitive follow&#x02010;up including time points prior to the biomarker assessment was 7.7 years (SD&#x000a0;=&#x000a0;1.93, range 1.39&#x02013;10.49 years). The mean age of the full sample at baseline was 63 years, 72% were female, and 39% were <italic toggle="yes">APOE</italic> &#x003b5;4 carriers. The demographic and clinical profiles of the plasma (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;215), CSF (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;159), and PET (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;155) samples is presented in Table&#x000a0;<xref rid="alz14537-tbl-0001" ref-type="table">1</xref>; the breakdown by AT biomarker groups can be found in Tables <xref rid="alz14537-supinfo-0001" ref-type="">S1&#x02013;S3</xref>. The mean cognitive follow&#x02010;up was 5.65 years (SD&#x000a0;=&#x000a0;1.45, range 1.01&#x02013;10.47) after plasma classification, 5.57 years (SD&#x000a0;=&#x000a0;1.48, range 1.00&#x02013;10.00) after CSF classification, and 4.18 years (SD&#x000a0;=&#x000a0;1.49, range 1.02&#x02013;6.07) after PET classification. The full cognitive follow&#x02010;up length, which for most participants included evaluations prior to the biomarker assessment, was 7.63 years (SD&#x000a0;=&#x000a0;1.94, range: 1.00&#x02013;10.47) for the plasma sample, 7.59 years (SD&#x000a0;=&#x000a0;1.89, range: 1.89&#x02013;10.47) for the CSF sample, and 8.11 (SD&#x000a0;=&#x000a0;1.76, range: 2.99&#x02013;10.49) for the PET sample.</p></sec><sec id="alz14537-sec-0140"><label>3.2</label><title>AT classification across biomarkers</title><p>Using A&#x003b2;<sub>42/40</sub> and p&#x02010;tau217 plasma biomarkers to classify participants, 10% (21/215) were classified as A+T+, 28% (60/215) as A+T&#x02212;, 3% (7/215) as A&#x02212;T+, and 59% (127/215) as A&#x02212;T&#x02212;. Using A&#x003b2;<sub>42/40</sub> and p&#x02010;tau217 CSF biomarkers, 11% (18/159) were classified as A+T+, 3% (5/159) as A+T&#x02212;, 2% (3/159) as A&#x02212;T+, and 84% (133/159) as A&#x02212;T&#x02212;. Finally, using PET biomarkers, 5% (8/155) were classified as A+T+, 29% (45/155) as A+T&#x02212;, 1% (1/155) as A&#x02212;T+, and 65% (101/155) as A&#x02212;T&#x02212;. While the proportion of CU A+T+ participants classified with PET was low, it is similar to what has been found in other PET studies<xref rid="alz14537-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz14537-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> and can probably be explained by that fact that most individuals positive on both PET markers have cognitive impairments. In line with previous studies, using the entorhinal cortex rather than a temporal meta&#x02010;ROI to classify tau positivity slightly increased the number of A+T+ participants.<xref rid="alz14537-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz14537-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p></sec><sec id="alz14537-sec-0150"><label>3.3</label><title>Rate of progression from CU to MCI across AT groups when defined using fluid versus neuroimaging biomarkers</title><p>Seventy&#x02010;six percent (16/21) of the A+T+<sub>plasma</sub> group developed MCI compared to 23% (14/60) in the A+T&#x02212;<sub>plasma</sub> group, 71% (5/7) in the A&#x02212;T+<sub>plasma</sub> group, and 21% (25/127) in the A&#x02212;T&#x02212; <sub>plasma</sub> group (Figure&#x000a0;<xref rid="alz14537-fig-0001" ref-type="fig">1A</xref>). The proportion of CU developing MCI was higher in the A+T+<sub>plasma</sub> group compared to A&#x02212;T&#x02212;<sub>plasma</sub> and A+T&#x02212; <sub>plasma</sub> groups (Fisher exact <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001). While the A&#x02212;T+<sub>plasma</sub> group was small it nevertheless included a higher proportion of participants who developed MCI compared to the A+T&#x02212;<sub>plasma</sub> and A&#x02212;T&#x02212;<sub>plasma</sub> groups (Fisher exact <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.02, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.006, respectively). When the groups were classified using CSF, 72% (13/18) of the A+T+<sub>CSF</sub>, 20% (1/5) of the A+T&#x02212;<sub>CSF</sub> group, 33% (1/3) of the A&#x02212;T+, and 18% (24/133) of the A&#x02212;T&#x02212;<sub>CSF</sub> group developed MCI (Figure&#x000a0;<xref rid="alz14537-fig-0001" ref-type="fig">1B</xref>). An increased CU to MCI progression rate was found in the A+T+<sub>CSF</sub> group compared to A&#x02212;T&#x02212;<sub>CSF</sub>, but no differences were found compared to the A+T&#x02212;<sub>CSF</sub> group (Fisher exact <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001 and <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.06, respectively). In the PET groups, 100% (8/8) of A+T+<sub>PET</sub> biomarker group, 44% (20/45) of the A+T&#x02212;<sub>PET</sub> group, 100% (1/1) of the A&#x02212;T+, and 20% (20/101) of the A&#x02212;T&#x02212;<sub>PET</sub> group progressed to MCI (Figure&#x000a0;<xref rid="alz14537-fig-0001" ref-type="fig">1C</xref>). The A+T+<sub>PET</sub> group was associated with increased progression to MCI compared to A&#x02212;T&#x02212;<sub>PET</sub> and A+T&#x02212;<sub>PET</sub> (Fisher exact <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.005, respectively). We also found differences between the A+T&#x02212;<sub>PET</sub> and A&#x02212;T&#x02212;<sub>PET</sub> groups (Fisher exact <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.005). One hundred twenty&#x02010;eight of these 155 PET participants were included in a previously published study,<xref rid="alz14537-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> which showed that 55% of A+T+<sub>PET</sub>, 9% of A+T&#x02212;<sub>PET</sub>, and 10% of A&#x02212;T&#x02212;<sub>PET</sub> participants developed MCI when followed for a mean of 3.16 years after the AT classification. Now with an additional 2.4 years of cognitive follow&#x02010;up, 100% of these A+T+<sub>PET</sub>, 44% of these A+T&#x02212;<sub>PET</sub>, and 20% of these A&#x02212;T&#x02212;<sub>PET</sub> have developed MCI.</p><fig position="float" fig-type="FIGURE" id="alz14537-fig-0001"><label>FIGURE 1</label><caption><p>Clinical progression to MCI across plasma, CSF, and PET AT biomarker groups. Bar graphs represent the proportion of participants who developed MCI across (A) plasma A&#x003b2;<sub>42/40</sub> and p&#x02010;tau217, (B) CSF A&#x003b2;<sub>42/40</sub> and p&#x02010;tau217, and (C) PET biomarker profiles measured with <sup>18</sup>F&#x02010;NAV4694 and <sup>18</sup>F&#x02010;flortaucipir. Survival curves reflecting the progression to MCI across (D) plasma, (E) CSF, and (F) PET biomarker groups. The vertical ticks on the curves refer to censored participants, that is, the lack of follow&#x02010;up of the individuals. G&#x02013;I, Forest plots showing HR and 95% confidence intervals from the survival analyses. Linear mixed effects models show the total RBANS cognitive score over time across (J) plasma, (K) CSF, and (L) PET biomarker profiles. The linear mixed effects models analyses included annual cognitive data before and after plasma, CSF, and PET measures. Models included age at biomarker measurement, sex, and years of education as covariates. Tau PET positivity was determined using temporal meta&#x02010;ROI. The A&#x02212;T&#x02212; group was used as reference. The A&#x02212;T+ in the PET (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;1) biomarker group is displayed for visualization purposes but was not included in the statistical analyses. The exact number of participants per group can be found in the first column of the lower part of panel (D), (E), and (F; number at risk at time 0). <sup>*</sup>
<italic toggle="yes">P&#x000a0;</italic>&#x0003c;&#x000a0;0.05, <italic toggle="yes">
<sup>**</sup>P&#x000a0;</italic>&#x0003c;&#x000a0;0.01, <italic toggle="yes">
<sup>***</sup>p&#x000a0;</italic>&#x0003c;&#x000a0;0.001. A&#x003b2;, amyloid beta; AT, amyloid, tau; CSF, cerebrospinal fluid; CU_CU, cognitively unimpaired older adults at the time of the biomarker measurement and remained cognitively unimpaired during follow&#x02010;up; CU_MCI, cognitively unimpaired older adults at the time of the biomarker measurement, who progressed to mild cognitive impairment during follow&#x02010;up; HR, hazard ratio; MCI, mild cognitive impairment; PET, positron emission tomography; p&#x02010;tau, phosphorylated tau; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; SE, standard error.</p></caption><graphic xlink:href="ALZ-21-e14537-g003" position="anchor" id="jats-graphic-1"/></fig><p>Results were replicated when restricting the sample size to the participants with all biomarker measurements, with all A+T+ groups showing a higher percentage of progression compared to their respective A&#x02212;T&#x02212; groups (the % of CU who progressed to MCI was 88% with plasma, 86% with CSF, and 100% with PET in the A+T+ compared to 14%&#x02013;20% in the A&#x02212;T&#x02212; groups, Figure <xref rid="alz14537-supinfo-0001" ref-type="">S4</xref> in supporting information). Using the entorhinal cortex rather than the temporal meta&#x02010;ROI increased the number of T+<sub>PET</sub> participants by &#x0003e; 50% (20 instead of 9), and yields results more similar to the CSF and plasma classification with 91% of A+T+ progressors in the restricted sample, 30% of A+T&#x02212;, 50% of A&#x02212;T&#x02212;, and 20% of A&#x02212;T&#x02212;, results that were almost identical in the full sample (Figure <xref rid="alz14537-supinfo-0001" ref-type="">S5</xref> in supporting information).</p><p>Cox proportional hazard models showed a higher risk of progression from CU to MCI among the A+T+<sub>plasma</sub> and A&#x02212;T+<sub>plasma</sub> (hazard ratio [HR]&#x000a0;=&#x000a0;7.81, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, 95% confidence interval [CI]&#x000a0;=&#x000a0;3.92 to 15.59; HR&#x000a0;=&#x000a0;4.25; <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.004, 95% CI&#x000a0;=&#x000a0;1.60 to 11.31; model concordance value [model fit]&#x000a0;=&#x000a0;0.72; standard error [SE]&#x000a0;=&#x000a0;0.04; Figure&#x000a0;<xref rid="alz14537-fig-0001" ref-type="fig">1D,G</xref>) compared to the A&#x02212;T&#x02212;<sub>plasma</sub> (reference) group. There were no differences between A+T&#x02212;<sub>plasma</sub> and A&#x02212;T&#x02212;<sub>plasma</sub> group (HR&#x000a0;=&#x000a0;1.14, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.69, 95% CI&#x000a0;=&#x000a0;0.58 to 2.24). In the CSF sample, we found an increase in the risk among A+T+<sub>CSF</sub> (HR&#x000a0;=&#x000a0;3.63, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, 95% CI&#x000a0;=&#x000a0;1.72 to 7.70; model concordance value&#x000a0;=&#x000a0;0.68; SE&#x000a0;=&#x000a0;0.06; Figure&#x000a0;<xref rid="alz14537-fig-0001" ref-type="fig">1E,H</xref>) compared to the A&#x02212;T&#x02212;<sub>CSF</sub> group. No differences were found comparing the reference group to either A+T&#x02212;<sub>CSF</sub> or A&#x02212;T+<sub>CSF</sub> (HR&#x000a0;=&#x000a0;1.50; <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.69, 95% CI&#x000a0;=&#x000a0;0.19 to 11.69; HR&#x000a0;=&#x000a0;3.82, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.20, 95% CI&#x000a0;=&#x000a0;0.50 to 29.24, respectively). Finally, A+T+<sub>PET</sub> and A+T&#x02212;<sub>PET</sub> participants exhibited a higher risk of MCI progression compared to A&#x02212;T&#x02212;<sub>PET</sub> (HR&#x000a0;=&#x000a0;9.30, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, 95% CI&#x000a0;=&#x000a0;3.67 to 23.55; HR&#x000a0;=&#x000a0;2.75, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.002, 95% CI&#x000a0;=&#x000a0;1.43 to 5.27; model concordance value&#x000a0;=&#x000a0;0.73; SE&#x000a0;=&#x000a0;0.04; Figure&#x000a0;<xref rid="alz14537-fig-0001" ref-type="fig">1F,I</xref>). The A&#x02212;T+ group was not included in the analyses given that only one participant was classified as A&#x02212;T+<sub>PET</sub>; this participant nevertheless developed MCI during the study follow&#x02010;up. Results were replicated in the subsample of 93 participants with all biomarkers (Figure <xref rid="alz14537-supinfo-0001" ref-type="">S4</xref>).</p><p>Finally, while not blind to biomarker status, all A+T+ MCI later seen in a clinical setting were classified as having MCI due to AD and &#x02248; 33% of them have now progressed to dementia while none of the A&#x02212;T&#x02212; received a diagnosis of AD, none progressed to dementia, and &#x02248; 25% were considered to have only subjective cognitive decline (Figure <xref rid="alz14537-supinfo-0001" ref-type="">S3</xref>).</p></sec><sec id="alz14537-sec-0160"><label>3.4</label><title>Cognitive trajectories</title><p>We also investigated the longitudinal cognitive performance of participants within the AT biomarker groups using plasma, CSF, and PET biomarkers while taking advantage of all cognitive time points, including the ones before the biomarkers&#x02019; classifications, when available. The A+T+<sub>plasma</sub> and A&#x02212;T+<sub>plasma</sub> groups demonstrated steeper cognitive declines compared to A&#x02212;T&#x02212;<sub>plasma</sub> (reference) group (<italic toggle="yes">&#x003b2;</italic>&#x000a0;=&#x000a0;&#x02212;1.03, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, SE&#x000a0;=&#x000a0;0.26, 95% CI&#x000a0;=&#x000a0;&#x02212;1.53 to &#x02212;0.52; <italic toggle="yes">&#x003b2;</italic>&#x000a0;=&#x000a0;&#x02013;1.00, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.02, SE&#x000a0;=&#x000a0;0.42, 95% CI&#x000a0;=&#x000a0;&#x02212;1.83 to &#x02212;0.18; <italic toggle="yes">R</italic>
<sup>2</sup>&#x000a0;=&#x000a0;0.12; Figure&#x000a0;<xref rid="alz14537-fig-0001" ref-type="fig">1J</xref>), while no differences were observed between the A&#x02212;T&#x02212;<sub>plasma</sub> and A+T&#x02212;<sub>plasma</sub> groups (<italic toggle="yes">&#x003b2;</italic>&#x000a0;=&#x000a0;0.01, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.96, SE&#x000a0;=&#x000a0;0.15, 95% CI&#x000a0;=&#x000a0;&#x02212;0.29 to 0.31). Using CSF to classify participants, the A+T+<sub>CSF</sub> group showed a faster decline over time compared to A&#x02212;T&#x02212;<sub>CSF</sub> (<italic toggle="yes">&#x003b2;</italic>&#x000a0;=&#x000a0;&#x02212;1.24, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, SE&#x000a0;=&#x000a0;0.24, 95% CI&#x000a0;=&#x000a0;&#x02212;1.72 to &#x02212;0.77; <italic toggle="yes">R</italic>
<sup>2</sup>&#x000a0;=&#x000a0;0.11; Figure&#x000a0;<xref rid="alz14537-fig-0001" ref-type="fig">1K</xref>), but no differences were found between the reference group and A+T&#x02212;<sub>CSF</sub> or the A&#x02212;T+<sub>CSF</sub> groups (<italic toggle="yes">&#x003b2;</italic>&#x000a0;=&#x000a0;0.13, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.77, SE&#x000a0;=&#x000a0;0.44, 95% CI&#x000a0;=&#x000a0;&#x02212;0.74 to 1.00; <italic toggle="yes">&#x003b2;</italic>&#x000a0;=&#x000a0;0.33, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.48, SE&#x000a0;=&#x000a0;0.47, 95% CI&#x000a0;=&#x000a0;&#x02212;0.58 to 1.24). When the groups were classified based on PET, the A+T+<sub>PET</sub> group demonstrated a steeper cognitive decline compared to A&#x02212;T&#x02212;<sub>PET</sub> (<italic toggle="yes">&#x003b2;</italic>&#x000a0;=&#x000a0;&#x02212;1.66, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, SE&#x000a0;=&#x000a0;0.38, 95% CI&#x000a0;=&#x000a0;&#x02212;2.40 to &#x02212;0.91; Figure&#x000a0;<xref rid="alz14537-fig-0001" ref-type="fig">1L</xref>). The A+T&#x02212;<sub>PET</sub> group demonstrated no differences compared to A&#x02212;T&#x02212;<sub>PET</sub> group (<italic toggle="yes">&#x003b2;</italic>&#x000a0;=&#x000a0;&#x02212;0.27, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.10, SE&#x000a0;=&#x000a0;0.16, 95% CI&#x000a0;=&#x000a0;&#x02212;0.59 to 0.05). Identical results were found in the subsample of 93 participants (see Figure <xref rid="alz14537-supinfo-0001" ref-type="">S4J&#x02013;L</xref> for more details).</p></sec><sec id="alz14537-sec-0170"><label>3.5</label><title>Concordance between different biomarkers modalities</title><p>We found weak correlation between plasma A&#x003b2;<sub>42/40</sub> and A&#x003b2; PET (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;&#x02212;0.35, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, Figure&#x000a0;<xref rid="alz14537-fig-0002" ref-type="fig">2A</xref>), and between plasma p&#x02010;tau217 and tau PET (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;0.38, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, Figure&#x000a0;<xref rid="alz14537-fig-0002" ref-type="fig">2B</xref>), but moderate correlations between plasma and CSF A&#x003b2;<sub>42/40</sub> (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;0.48, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, Figure&#x000a0;<xref rid="alz14537-fig-0002" ref-type="fig">2C</xref>) and plasma and CSF p&#x02010;tau217 (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;0.51, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, Figure&#x000a0;<xref rid="alz14537-fig-0002" ref-type="fig">2D</xref>). Similarly, CSF A&#x003b2;<sub>42/40</sub> and CSF p&#x02010;tau217 showed weak to moderate correlation with both A&#x003b2; and tau PET (<italic toggle="yes">r</italic>&#x000a0;=&#x000a0;&#x02212;0.58; <italic toggle="yes">r</italic>&#x000a0;=&#x000a0;0.40; <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, respectively, Figure&#x000a0;<xref rid="alz14537-fig-0002" ref-type="fig">2E,F</xref>). When evaluating concordance using A&#x003b2; and tau status as categorical variables with Cohen kappa, we found weak agreement between plasma A&#x003b2;<sub>42/40</sub> and A&#x003b2; PET (kappa&#x000a0;=&#x000a0;0.33, 95% CI&#x000a0;=&#x000a0;0.17 to 0.49), and between plasma p&#x02010;tau217 and tau PET (kappa&#x000a0;=&#x000a0;0.42, 95% CI&#x000a0;=&#x000a0;0.19 to 0.64). The agreement was also weak between plasma and CSF A&#x003b2;<sub>42/40</sub> (kappa&#x000a0;=&#x000a0;0.30, 95% CI&#x000a0;=&#x000a0;0.16 to 0.43), but moderate to strong agreement for plasma and CSF p&#x02010;tau217 (kappa&#x000a0;=&#x000a0;0.60, 95% CI&#x000a0;=&#x000a0;0.41 to 0.80). For CSF and PET A&#x003b2; and tau status, the agreement was moderate for A&#x003b2;, but weak for tau (kappa&#x000a0;=&#x000a0;0.51, 95% CI&#x000a0;=&#x000a0;0.32 to 0.69; kappa&#x000a0;=&#x000a0;0.36, 95% CI&#x000a0;=&#x000a0;0.10 to 0.62, respectively). See Figure <xref rid="alz14537-supinfo-0001" ref-type="">S6</xref> in supporting information for the concordance when stratified by&#x000a0;positive/negative&#x000a0;status and for the percentage of participants who progressed to MCI by biomarker status.</p><fig position="float" fig-type="FIGURE" id="alz14537-fig-0002"><label>FIGURE 2</label><caption><p>Scatterplots reflecting concordance status among plasma, CSF, and PET A&#x003b2; and tau biomarkers. Correlation plots of (A) plasma A&#x003b2;42/40&#x000a0;versus A&#x003b2; PET biomarkers; (B) plasma p&#x02010;tau217 versus tau PET biomarkers; (C) plasma A&#x003b2;42/40&#x000a0;versus CSF A&#x003b2;42/40 biomarkers; (D) plasma p&#x02010;tau217 versus CSF p&#x02010;tau217 biomarkers; (E) CSF A&#x003b2;42/40&#x000a0;versus A&#x003b2; PET biomarkers; (F) CSF p&#x02010;tau217 versus tau PET biomarkers. Colors indicate participants&#x02019; cognitive status and symbols indicate A&#x003b2;/tau positive or negative status. Vertical and horizontal dashed lines correspond to plasma, PET, and CSF biomarker cutoff values, respectively. Cutoff values were 0.09 for plasma A&#x003b2;42/40; 0.072 for CSF A&#x003b2;42/40; 1.26 SUVR for A&#x003b2; PET; 3.98&#x000a0;pg/mL for plasma p&#x02010;tau217; 400.19 pg/mL for CSF p&#x02010;tau217; and 1.29 SUVR for temporal meta&#x02010;ROI tau PET. <italic toggle="yes">n</italic>&#x000a0;=&#x000a0;143 participants had both plasma and PET measurements, <italic toggle="yes">n</italic>&#x000a0;=&#x000a0;158 had both plasma and CSF measurements, and <italic toggle="yes">n</italic>&#x000a0;=&#x000a0;93 had both CSF and PET measurements. A&#x003b2;, amyloid beta; CSF, cerebrospinal fluid; CU_CU, cognitively unimpaired older adults at the time of the biomarker measurement and remained cognitively unimpaired during follow&#x02010;up; CU_MCI, cognitively unimpaired older adults at the time of the biomarker measurement, who progressed to mild cognitive impairment during follow&#x02010;up; PET, positron emission tomography; p&#x02010;tau, phosphorylated tau; SUVR, standardized uptake value ratio</p></caption><graphic xlink:href="ALZ-21-e14537-g001" position="anchor" id="jats-graphic-3"/></fig></sec><sec id="alz14537-sec-0180"><label>3.6</label><title>Direct comparisons between fluid and imaging biomarkers</title><p>A&#x003b2;, tau, and the combination of tau + A&#x003b2; models were comparable using the Vuong test. Comparing the performance of A&#x003b2; models, A&#x003b2; PET showed the best model fit compared to plasma and CSF A&#x003b2;<sub>42/40</sub> models (<italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.05). Also, all ROC models were similar using the DeLong test, with AUC ranging from 0.66 to 0.75 for A&#x003b2;, from 0.74 to 0.81 for tau, and between 0.77 to 0.82 for their combinations (Figure&#x000a0;<xref rid="alz14537-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="FIGURE" id="alz14537-fig-0003"><label>FIGURE 3</label><caption><p>Discriminative accuracy of plasma, CSF, and PET biomarkers for identifying individuals who will progress to MCI. ROC curves and corresponding AUC showing the discriminative ability of (A) individual plasma, CSF, and PET A&#x003b2; models; (B) individual plasma, CSF, and PET tau models; and (C) models combining plasma A&#x003b2;<sub>42/40</sub>, CSF A&#x003b2;<sub>42/40</sub>, and A&#x003b2; PET biomarkers with plasma p&#x02010;tau217, CSF p&#x02010;tau217, and tau PET in distinguishing between individuals who remained cognitively normal versus those who developed MCI. A&#x003b2;, amyloid beta; AUC, area under the curve; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; PET, positron emission tomography; ROC, receiver operating characteristic</p></caption><graphic xlink:href="ALZ-21-e14537-g002" position="anchor" id="jats-graphic-5"/></fig><p>Finally, tau biomarker cutoffs used in Figure&#x000a0;<xref rid="alz14537-fig-0001" ref-type="fig">1</xref>, which are hypothesized as being optimal to identify AD pathology, gave good to excellent specificity (97% for plasma, 95% for CSF, and 100% for PET), but low sensitivity (34%, 45%, and 17%, respectively) at identifying CU who will develop MCI. Except for CSF, A&#x003b2; biomarker cutoffs had low specificity (66% for plasma, 94% for CSF, and 77% for PET), and low sensitivity (65%, 45%, and 55%, respectively). See Tables <xref rid="alz14537-supinfo-0001" ref-type="">S7&#x02013;S12</xref> for the sensitivity, specificity, negative predictive value, and positive predictive value of all other possible cutoffs.</p></sec></sec><sec id="alz14537-sec-0190"><label>4</label><title>DISCUSSION</title><p>We assessed the performance of plasma p&#x02010;tau217, alone or combined with plasma A&#x003b2;<sub>42/40</sub>, at identifying CU individuals who will develop MCI in a 10&#x02010;year window (the mean follow&#x02010;up being 6 years after plasma measurement with follow&#x02010;ups ranging from 1 to 10 years). In the main analyses, p&#x02010;tau217 and A&#x003b2;<sub>42/40</sub> were stratified, since stratification is important for clinical use. For instance, only individuals with A&#x003b2; pathology are enrolled in anti&#x02010;amyloid trials or can receive medication to slow down AD. For most diseases, clinical diagnosis is also based on a threshold delimitating what is considered in the normal range versus what is abnormal. Given that there are no universal thresholds for plasma markers, and because plasma values vary depending on analytic techniques, we also showed the results using continuous variables. Finally, the analyses were replicated using CSF and PET biomarkers, the latter being the gold standard to quantify amyloid and tau pathology in vivo.</p><p>For all biomarkers assessed, we found that A+T+ individuals had a higher risk of progression to MCI compared to the A&#x02212;T&#x02212; group. While only few individuals were classified as A&#x02212;T+ across biomarkers, A&#x02212;T+<sub>plasma</sub> individuals were also at increased risk of progression to MCI compared to A&#x02212;T&#x02212;<sub>plasma</sub> individuals. Supporting these results, the ROC analyses suggest that the accuracy of plasma p&#x02010;tau217 was similar to that found with CSF p&#x02010;tau217 or PET biomarkers and that the models were not improved when combining amyloid with the tau markers. Finally, all T+ participants developed MCI within 5 years when identifying T+ individuals based on both neocortical and medial temporal lobe regions (temporal meta&#x02010;ROI), but this T+ classification yielded&#x000a0;&#x0003e;&#x000a0;50% fewer T+ participants than when exclusively using the entorhinal cortex or the p&#x02010;tau217 fluid biomarkers (Figure&#x000a0;<xref rid="alz14537-fig-0001" ref-type="fig">1</xref> and Figure <xref rid="alz14537-supinfo-0001" ref-type="">S5</xref>). In line with these results, CU individuals with neocortical tau were found to be at increased risk of progression to dementia compared to CU individuals with medial temporal tau.<xref rid="alz14537-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>Robust and accurate blood&#x02010;based markers for AD are needed for clinical evaluation, trial recruitment, and to identify individuals who could benefit from disease&#x02010;modifying therapies.<xref rid="alz14537-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="alz14537-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="alz14537-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="alz14537-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> Plasma p&#x02010;tau217 has been found to differentiate CU from individuals with clinical AD;<xref rid="alz14537-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> it can detect AD pathology in individuals with MCI;<xref rid="alz14537-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> and it correlates with A&#x003b2; PET, tau PET, and cognitive decline in CU participants.<xref rid="alz14537-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="alz14537-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="alz14537-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="alz14537-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="alz14537-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> Our prospective study shows that plasma p&#x02010;tau217 can also be used to predict the development of MCI in CU individuals years before cognitive onset. It also stresses the fact that CU individuals with tau pathology have a brain disease that will lead to cognitive impairments if not treated and that finding a preventive treatment for these individuals is therefore a priority.</p><p>Regardless of the biomarker, A&#x003b2; did not improve the predictive value of the tau biomarkers, even when using IP&#x02010;MS to quantify plasma, which is known to be a more accurate technique than immunoassay.<xref rid="alz14537-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> This can mainly be explained by the fact that almost all T+ individuals were also A+.<xref rid="alz14537-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> The finding is also consistent with previous studies that have demonstrated A&#x003b2; proteins plateau earlier in the AD spectrum, whereas p&#x02010;tau levels continue to increase in the prodromal stages of the disease making A&#x003b2; less useful for predicting cognitive changes.<xref rid="alz14537-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> As for individuals with abnormal A&#x003b2; but normal tau biomarkers, their risk of progression to MCI was only increased when classified with temporal meta&#x02010;ROI tau PET compared to the A&#x02212;T&#x02212; group. This can be attributed to the fact that fluid biomarkers capture soluble and diffusible proteins, while PET images capture insoluble aggregates that are characteristic of later stages of the disease.<xref rid="alz14537-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Individuals classified as positive on an A&#x003b2; PET scan who are not yet positive on a tau PET scan probably have some level of tau that is not yet detected by a PET scan. This might be particularly true when T+ is defined based on neocortical regions.<xref rid="alz14537-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Supporting this hypothesis, 10% of the participants were tau positive on plasma p&#x02010;tau217 while negative on tau PET, and only 1% had the inverse profile. Most (79%) of these tau plasma positive and tau PET negative also developed MCI. Furthermore, 128 participants included in the current PET subsample were included in a previous publication. While only 9% of the A+T&#x02212; participants had developed MCI after a follow&#x02010;up of 3.4 years in this previous publication, 2.4 years later, 42% of them (54/129) now have MCI.<xref rid="alz14537-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> These results suggest that most A+T&#x02212; PET participants will also develop cognitive impairments if followed for &#x0003e; 4 years. Such a conclusion cannot be made with fluid biomarkers. It is possible that plasma and CSF A+T&#x02212; individuals are further away in the disease process, or that soluble A&#x003b2; is not sufficient to cause AD. Finally, the direct comparison between plasma and CSF A&#x003b2;<sub>42/40</sub> suggests that plasma might become abnormal prior to CSF (Figure&#x000a0;<xref rid="alz14537-fig-0002" ref-type="fig">2C</xref>), a finding that will need to be replicated.</p><p>Twenty&#x02010;seven percent of our participants developed MCI during a mean cognitive follow&#x02010;up of 7.7 years (SD&#x000a0;=&#x000a0;1.93, range 1.39&#x02013;10.49 years), which is a percentage similar to what has been found in a recent community&#x02010;based study.<xref rid="alz14537-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> The unimpaired versus impaired cognitive classification was based on research data done blind to <italic toggle="yes">APOE</italic> &#x003b5;4 status and MRI, CSF, and PET biomarker results. Not all MCI individuals are therefore on the path toward AD dementia. MCI can develop for multiple reasons and most A&#x02212;T&#x02212; individuals probably have non&#x02010;neurodegenerative conditions such as vascular or psychiatric conditions.<xref rid="alz14537-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> Approximately 60% of individuals classified as MCI were later followed in a clinical setting unblind to biomarker status and one third of the A+T+ have now developed dementia while none of the A&#x02212;T&#x02212; followed in an affiliated clinical setting developed dementia and one third of the A&#x02212;T&#x02212;&#x000a0;are now considered to only have subjective cognitive impairment (Figure <xref rid="alz14537-supinfo-0001" ref-type="">S3</xref>). Finally, the selected thresholds were not sensitive at identifying all causes of MCI (Table <xref rid="alz14537-supinfo-0001" ref-type="">S7&#x02013;S12</xref>). The thresholds were selected to optimize the detection of AD pathology, not to detect MCI with no AD pathology. The sensitivity of all possible thresholds at identifying all causes of MCI can nevertheless be found in supporting information.</p><p>One main limitation is the low racial, ethnic (98% White), and sex imbalance (72% female) of our population, as the findings may not be generalizable to all populations. The low sample size in the A+T+ and the A&#x02212;T+ groups should also be noted. The percentage of participants included in these groups is nevertheless similar to what was found in previous PET studies involving preclinical cohorts.<xref rid="alz14537-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz14537-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Given this limitation and the fact that 20% of our reference group developed MCI, the HRs between groups should be interpreted with caution. Finally, part of the study follow&#x02010;up occurred during the COVID&#x02010;19 pandemic, which may have contributed to the development or deterioration of cognitive impairment.<xref rid="alz14537-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>
</p><p>In this longitudinal multimodal biomarker study of individuals with a first&#x02010;degree family history of AD dementia spanning &#x0003e; 10 years, 27% developed MCI based on a multidisciplinary classification consensus meeting blind to AD biomarkers and <italic toggle="yes">APOE</italic> genotype information. While not interchangeable, fluid and PET biomarkers of AD pathology are both extremely valuable for identifying individuals who will develop MCI, with almost all individuals with abnormal p&#x02010;tau217 values developing MCI within a 10&#x02010;year follow&#x02010;up. While these results suggest that p&#x02010;tau217 quantified in a specialized center can be used as a stand&#x02010;alone test to identify CU who will develop MCI, plasma and CSF biomarkers are known to be more prone to measurement errors, matrix effects, and batch&#x02010;to&#x02010;batch variability compared to PET.<xref rid="alz14537-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>, <xref rid="alz14537-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Such limitations need to be considered when implementing plasma p&#x02010;tau217 in memory clinics. Given the possible distress caused by the disclosure of the biomarker results and the lack of preventive treatments, we also strongly advocate that people who do not yet have cognitive impairments should not be tested or diagnosed based on plasma (or PET) biomarkers in clinical settings, and restricting the use of plasma p&#x02010;tau217, CSF p&#x02010;tau217, and tau PET to research settings and specialized clinics where counseling is available.</p></sec><sec id="alz14537-sec-0200"><title>AUTHOR CONTRIBUTIONS</title><p>Yara Yakoub, Cherie Strikwerda&#x02010;Brown, Nicholas J. Ashton, Michael Sch&#x000f6;ll, Pedro Rosa&#x02010;Neto, Judes Poirier, John C. S. Breitner, Henrik Zetterberg, Kaj Blennow, and Sylvia Villeneuve contributed to the study concept and design. Yara Yakoub, Fernando Gonzalez&#x02010;Ortiz, Nicholas J. Ashton, Christine Dery, Fr&#x000e9;d&#x000e9;ric St&#x02010;Onge, Valentin Ourry,&#x000a0;Maiya Geddes, Simon Ducharme, Maxime Montembeault, and Jean&#x02010;Paul Soucy contributed to data acquisition and analysis. Yara Yakoub and Sylvia Villeneuve drafted the manuscript and figures.</p></sec><sec sec-type="COI-statement" id="alz14537-sec-0220"><title>CONFLICT OF INTEREST STATEMENT</title><p>H.Z. has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche; and is a co&#x02010;founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). M.S. has served on advisory boards for Roche, Novo Nordisk, and Servier; received speaker honoraria from Bioarctic, Eisai, Genentech, Novo Nordisk, and Roche; and receives research support (to the institution) from Alzpath, Bioarctic, Novo Nordisk, and Roche (outside scope of submitted work). He is a co&#x02010;founder of Centile Bioscience Ltd. No other disclosures were reported. Author disclosures are available in the <xref rid="alz14537-supinfo-0001" ref-type="">supporting information</xref>.</p></sec><sec id="alz14537-sec-0230"><title>CONSENT STATEMENT</title><p>Written informed consent was obtained for all PREVENT&#x02010;AD participants. All research procedures were approved by the institutional review board at McGill University.</p></sec><sec id="alz14537-sec-0260"><title>CODE AVAILABILITY</title><p>The code used for the statistical analyses is available from the first author upon request. The analyses and figures were built using R programming language (v.4.2.2) and R studio &#x0201c;Elsbeth Geranium&#x0201d; Release (7d165dcfc1b6d300eb247738db2c7076234f6ef0, 2022&#x02010;12&#x02010;03) for macOS (packages used for the main analyses: survival v3.4&#x02010;0; survminer v0.4.9; lme4 v1.1&#x02010;31; lmerTest v3.1&#x02010;3; ggplot v2.3.5.0; pROC v1.18.4).</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz14537-supinfo-0001" position="float" content-type="local-data"/><supplementary-material id="alz14537-supitem-0001" position="float" content-type="local-data"><caption><p>Supporting Information</p></caption><media xlink:href="ALZ-21-e14537-s002.docx"/></supplementary-material><supplementary-material id="alz14537-supitem-0002" position="float" content-type="local-data"><caption><p>Supporting Information</p></caption><media xlink:href="ALZ-21-e14537-s001.pdf"/></supplementary-material></sec></body><back><ack id="alz14537-sec-0210"><title>ACKNOWLEDGMENTS</title><p>The authors thank all the PREVENT&#x02010;AD participants and their families as well as all the PREVENT&#x02010;AD team members for their time and dedication. A complete listing of PREVENT&#x02010;AD contributors can be found at&#x000a0;<ext-link xlink:href="https://preventad.loris.ca/acknowledgements/acknowledgements.php?date" ext-link-type="uri">https://preventad.loris.ca/acknowledgements/acknowledgements.php?date</ext-link>=2024&#x02010;11&#x02010;29. The authors would like to acknowledge Alfonso Fajardo Valdez, Ting Qiu, Mohammadali Javanray, Jonathan Gallego Rudolf, Bery Mohammediyan, and Jordana Remz for providing advice on the study analyses; Jennifer Tremblay&#x02010;Mercier, Louise Hudon, Elisabeth Sylvain, Gabriel Jean, and Nolan&#x02010;Patrick Cunningham for their contributions to data collection; and Lobna Almasalmeh and the Neurokemi lab at Gothenburg University for their assistance in plasma and CSF sample processing. The project was funded by the Canadian Institutes of Health Research (CIHR) (#438655) and Brain Canada grants. Dr. Zetterberg is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023&#x02010;00356; #2022&#x02010;01018 and #2019&#x02010;02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG&#x02010;71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809&#x02010;2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF&#x02010;21&#x02010;831376&#x02010;C, #ADSF&#x02010;21&#x02010;831381&#x02010;C, #ADSF&#x02010;21&#x02010;831377&#x02010;C, and #ADSF&#x02010;24&#x02010;1284328&#x02010;C), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling&#x02010;Persson Family Foundation, Familjen R&#x000f6;nstr&#x000f6;ms Stiftelse, Stiftelsen f&#x000f6;r Gamla Tj&#x000e4;narinnor, Hj&#x000e4;rnfonden, Sweden (#FO2022&#x02010;0270), the European Union's Horizon 2020 research and innovation programme under the Marie Sk&#x00142;odowska&#x02212;Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme &#x02013; Neurodegenerative Disease Research (JPND2021&#x02010;00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI&#x02010;1003). Dr. Poirier is funded by CIHR, the J.L. Levesque Foundation, FRQS, and NSERC grants. Dr. St&#x02010;Onge was funded by a scholarship from the Fonds de Recherche du Quebec &#x02013; Sant&#x000e9; (FRQS). Dr. Soucy is funded by the CIHR, Brain Canada, and Biogen Canada. Dr. Sch&#x000f6;ll receives funding from the Knut and Alice Wallenberg Foundation (Wallenberg Centre for Molecular and Translational Medicine; KAW2014.0363 and KAW 2023.0371), the Swedish Research Council (2017&#x02010;02869, 2021&#x02010;02678, 2021&#x02010;06545 and 2023&#x02010;06188), the European Union's Horizon Europe research and innovation program under grant agreement no 101132933 (AD&#x02010;RIDDLE) and 101112145 (PROMINENT), the National Institute of Health (R01 AG081394&#x02010;01), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF&#x02010;agreement (ALFGBG&#x02010;813971 and ALFGBG&#x02010;965326), the Swedish Brain Foundation (FO2021&#x02010;0311), the Swedish Alzheimer Foundation (AF&#x02010;994900), the Sahlgrenska Academy at the University of Gothenburg, the V&#x000e4;stra G&#x000f6;taland Region R&#x00026;D (VGFOUREG&#x02010;995510) and Innovation platforms, Sahlgrenska Science Park and the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre.</p></ack><sec sec-type="data-availability" id="alz14537-sec-0250"><title>DATA AVAILABILITY STATEMENT</title><p>Data used in the preparation of this manuscript were obtained from the Pre&#x02010;symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT&#x02010;AD). Some of the data are publicly available (<ext-link xlink:href="https://openpreventad.loris.ca" ext-link-type="uri" specific-use="software is-supplemented-by">https://openpreventad.loris.ca</ext-link>&#x000a0;and&#x000a0;<ext-link xlink:href="https://registeredpreventad.loris.ca" ext-link-type="uri" specific-use="software is-supplemented-by">https://registeredpreventad.loris.ca</ext-link>), and the remaining data can be shared upon approval by the scientific committee at the Centre for Studies on Prevention of Alzheimer's Disease (StoP&#x02010;AD) at the Douglas Mental Health University Institute.</p></sec><ref-list id="alz14537-bibl-0001"><title>REFERENCES</title><ref id="alz14537-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz14537-cit-0001">
<string-name>
<surname>Jack</surname>
<given-names>CR</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Holtzman</surname>
<given-names>DM</given-names>
</string-name>. <article-title>Biomarker modeling of Alzheimer's disease</article-title>. <source>Neuron</source>. <year>2013</year>;<volume>80</volume>(<issue>6</issue>):<fpage>1347</fpage>&#x02010;<lpage>1358</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuron.2013.12.003</pub-id>
<pub-id pub-id-type="pmid">24360540</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz14537-cit-0002">
<string-name>
<surname>Jack</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Andrews</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Beach</surname>
<given-names>TG</given-names>
</string-name>, et al. <article-title>Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup</article-title>. <source>Alzheimer's &#x00026; dementia : the journal of the Alzheimer's Association</source>. <year>2024</year>; doi:<pub-id pub-id-type="doi">10.1002/alz.13859</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz14537-cit-0003">
<string-name>
<surname>Jack</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Blennow</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>NIA&#x02212;AA Research Framework: toward a biological definition of Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2018</year>;<volume>14</volume>(<issue>4</issue>):<fpage>535</fpage>&#x02010;<lpage>562</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2018.02.018</pub-id>
<pub-id pub-id-type="pmid">29653606</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz14537-cit-0004">
<string-name>
<surname>Strikwerda&#x02212;Brown</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hobbs</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Gonneaud</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>Association of elevated amyloid and tau positron emission tomography signal with near&#x02010;term development of Alzheimer disease symptoms in older adults without cognitive impairment</article-title>. <source>JAMA Neurol</source>. <year>2022</year>;<volume>79</volume>(<issue>10</issue>):<fpage>975</fpage>&#x02010;<lpage>985</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2022.2379</pub-id>
<pub-id pub-id-type="pmid">35907254</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz14537-cit-0005">
<string-name>
<surname>Ossenkoppele</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pichet Binette</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Groot</surname>
<given-names>C</given-names>
</string-name>, et&#x000a0;al. <article-title>Amyloid and tau PET&#x02212;positive cognitively unimpaired individuals are at high risk for future cognitive decline</article-title>. <source>Nat Med</source>. <year>2022</year>;<volume>28</volume>(<issue>11</issue>):<fpage>2381</fpage>&#x02010;<lpage>2387</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-022-02049-x</pub-id>
<pub-id pub-id-type="pmid">36357681</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz14537-cit-0006">
<string-name>
<surname>Thijssen</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>La Joie</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Strom</surname>
<given-names>A</given-names>
</string-name>, et&#x000a0;al. <article-title>Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study</article-title>. <source>Lancet Neurol</source>. <year>2021</year>;<volume>20</volume>(<issue>9</issue>):<fpage>739</fpage>&#x02010;<lpage>752</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s1474-4422(21)00214-3</pub-id>
<pub-id pub-id-type="pmid">34418401</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz14537-cit-0007">
<string-name>
<surname>Villemagne</surname>
<given-names>VL</given-names>
</string-name>, <string-name>
<surname>Lopresti</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Dor&#x000e9;</surname>
<given-names>V</given-names>
</string-name>, et&#x000a0;al. <article-title>What is T+?</article-title>. <source>J Nucl Med</source>. <year>2021</year>;<volume>62</volume>(<issue>5</issue>):<fpage>614</fpage>&#x02010;<lpage>619</lpage>. doi:<pub-id pub-id-type="doi">10.2967/jnumed.120.245423</pub-id>
<pub-id pub-id-type="pmid">33384320</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz14537-cit-0008">
<string-name>
<surname>Barth&#x000e9;lemy</surname>
<given-names>NR</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Joseph&#x02010;Mathurin</surname>
<given-names>N</given-names>
</string-name>, et&#x000a0;al. <article-title>A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease</article-title>. <source>Nat Med</source>. <year>2020</year>;<volume>26</volume>(<issue>3</issue>):<fpage>398</fpage>&#x02010;<lpage>407</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-020-0781-z</pub-id>
<pub-id pub-id-type="pmid">32161412</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz14537-cit-0009">
<string-name>
<surname>Montoliu&#x02010;Gaya</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Benedet</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Tissot</surname>
<given-names>C</given-names>
</string-name>, et&#x000a0;al. <article-title>Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies</article-title>. <source>Nat Aging</source>. <year>2023</year>;<volume>3</volume>(<issue>6</issue>):<fpage>661</fpage>&#x02010;<lpage>669</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s43587-023-00405-1</pub-id>
<pub-id pub-id-type="pmid">37198279</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz14537-cit-0010">
<string-name>
<surname>Verberk</surname>
<given-names>IMW</given-names>
</string-name>, <string-name>
<surname>Slot</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Verfaillie</surname>
<given-names>SCJ</given-names>
</string-name>, et&#x000a0;al. <article-title>Plasma amyloid as prescreener for the earliest Alzheimer pathological changes</article-title>. <source>Ann Neurol</source>. <year>2018</year>;<volume>84</volume>(<issue>5</issue>):<fpage>648</fpage>&#x02010;<lpage>658</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.25334</pub-id>
<pub-id pub-id-type="pmid">30196548</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz14537-cit-0011">
<string-name>
<surname>Tremblay&#x02010;Mercier</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Madjar</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Das</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Open science datasets from PREVENT&#x02010;AD, a longitudinal cohort of pre&#x02010;symptomatic Alzheimer's disease</article-title>. <source>Neuroimage Clin</source>. <year>2021</year>;<volume>31</volume>:<elocation-id>102733</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.nicl.2021.102733</pub-id>
<pub-id pub-id-type="pmid">34192666</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz14537-cit-0012">
<string-name>
<surname>Gonzalez&#x02010;Ortiz</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ferreira</surname>
<given-names>PCL</given-names>
</string-name>, <string-name>
<surname>Gonz&#x000e1;lez&#x02010;Escalante</surname>
<given-names>A</given-names>
</string-name>, et&#x000a0;al. <article-title>A novel ultrasensitive assay for plasma p&#x02010;tau217: performance in individuals with subjective cognitive decline and early Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>2</issue>):<fpage>1239</fpage>&#x02010;<lpage>1249</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13525</pub-id>
<pub-id pub-id-type="pmid">37975513</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz14537-cit-0013">
<string-name>
<surname>Meyer</surname>
<given-names>P&#x02010;F</given-names>
</string-name>, <string-name>
<surname>Ashton</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Karikari</surname>
<given-names>TK</given-names>
</string-name>, et&#x000a0;al. <article-title>Plasma p&#x02010;tau231, p&#x02010;tau181, PET biomarkers, and cognitive change in older adults</article-title>. <source>Annals Neurol</source>. <year>2022</year>;<volume>91</volume>(<issue>4</issue>):<fpage>548</fpage>&#x02010;<lpage>560</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.26308</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz14537-cit-0014">
<string-name>
<surname>Gobom</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Parnetti</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Rosa&#x02212;Neto</surname>
<given-names>P</given-names>
</string-name>, et&#x000a0;al. <article-title>Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid</article-title>. <source>Clin Chem Lab Med</source>. <year>2022</year>;<volume>60</volume>(<issue>2</issue>):<fpage>207</fpage>&#x02010;<lpage>219</lpage>. doi:<pub-id pub-id-type="doi">10.1515/cclm-2021-0651</pub-id>
<pub-id pub-id-type="pmid">34773730</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz14537-cit-0015">
<string-name>
<surname>Qiu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Z&#x02010;Q</given-names>
</string-name>, <string-name>
<surname>Rheault</surname>
<given-names>F</given-names>
</string-name>, et&#x000a0;al. <article-title>Structural white matter properties and cognitive resilience to tau pathology</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>5</issue>):<fpage>3364</fpage>&#x02010;<lpage>3377</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13776</pub-id>
<pub-id pub-id-type="pmid">38561254</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz14537-cit-0016">
<string-name>
<surname>Villeneuve</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rabinovici</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Cohn&#x02010;Sheehy</surname>
<given-names>BI</given-names>
</string-name>, et&#x000a0;al. <article-title>Existing Pittsburgh Compound&#x02010;B positron emission tomography thresholds are too high: statistical and pathological evaluation</article-title>. <source>Brain</source>. <year>2015</year>;<volume>138</volume>(<issue>7</issue>):<fpage>2020</fpage>&#x02010;<lpage>2033</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awv112</pub-id>
<pub-id pub-id-type="pmid">25953778</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz14537-cit-0017">
<string-name>
<surname>Jack</surname>
<given-names>CR</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Wiste</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Weigand</surname>
<given-names>SD</given-names>
</string-name>, et&#x000a0;al. <article-title>Defining imaging biomarker cut points for brain aging and Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2017</year>;<volume>13</volume>(<issue>3</issue>):<fpage>205</fpage>&#x02010;<lpage>216</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2016.08.005</pub-id>
<pub-id pub-id-type="pmid">27697430</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz14537-cit-0018">
<string-name>
<surname>Braak</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Braak</surname>
<given-names>E</given-names>
</string-name>. <article-title>Staging of Alzheimer's disease&#x02010;related neurofibrillary changes</article-title>. <source>Neurobiol Aging</source>. <year>1995</year>;<volume>16</volume>(<issue>3</issue>):<fpage>271</fpage>&#x02010;<lpage>278</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0197-4580(95)00021-6</pub-id>
<pub-id pub-id-type="pmid">7566337</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz14537-cit-0019">
<string-name>
<surname>Braak</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Braak</surname>
<given-names>E</given-names>
</string-name>. <article-title>Neuropathological stageing of Alzheimer&#x02010;related changes</article-title>. <source>Acta Neuropathol</source>. <year>1991</year>;<volume>82</volume>(<issue>4</issue>):<fpage>239</fpage>&#x02010;<lpage>259</lpage>. doi:<pub-id pub-id-type="doi">10.1007/bf00308809</pub-id>
<pub-id pub-id-type="pmid">1759558</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz14537-cit-0020">
<string-name>
<surname>Therriault</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Servaes</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tissot</surname>
<given-names>C</given-names>
</string-name>, et&#x000a0;al. <article-title>Equivalence of plasma p&#x02010;tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>(<issue>11</issue>):<fpage>4967</fpage>&#x02010;<lpage>4977</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13026</pub-id>
<pub-id pub-id-type="pmid">37078495</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz14537-cit-0021">
<string-name>
<surname>Petersen</surname>
<given-names>RC</given-names>
</string-name>. <article-title>Mild cognitive impairment as a diagnostic entity</article-title>. <source>J Intern Med</source>. <year>2004</year>;<volume>256</volume>(<issue>3</issue>):<fpage>183</fpage>&#x02010;<lpage>194</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2796.2004.01388.x</pub-id>
<pub-id pub-id-type="pmid">15324362</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz14537-cit-0022">
<string-name>
<surname>Hansson</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Blennow</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Zetterberg</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Dage</surname>
<given-names>J</given-names>
</string-name>. <article-title>Blood biomarkers for Alzheimer's disease in clinical practice and trials</article-title>. <source>Nat Aging</source>. <year>2023</year>;<volume>3</volume>(<issue>5</issue>):<fpage>506</fpage>&#x02010;<lpage>519</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s43587-023-00403-3</pub-id>
<pub-id pub-id-type="pmid">37202517</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz14537-cit-0023">
<string-name>
<surname>Hampel</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Cummings</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>Blood&#x02010;based biomarkers for Alzheimer's disease: current state and future use in a transformed global healthcare landscape</article-title>. <source>Neuron</source>. <year>2023</year>;<volume>111</volume>(<issue>18</issue>):<fpage>2781</fpage>&#x02010;<lpage>2799</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuron.2023.05.017</pub-id>
<pub-id pub-id-type="pmid">37295421</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz14537-cit-0024">
<string-name>
<surname>Mattsson&#x02010;Carlgren</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Collij</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Stomrud</surname>
<given-names>E</given-names>
</string-name>, et&#x000a0;al. <article-title>Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies</article-title>. <source>JAMA Neurol</source>. <year>2024</year>;<volume>81</volume>(<issue>1</issue>):<fpage>69</fpage>&#x02010;<lpage>78</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2023.4596</pub-id>
<pub-id pub-id-type="pmid">38048096</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz14537-cit-0025">
<string-name>
<surname>Mattsson&#x02010;Carlgren</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Salvad&#x000f3;</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Ashton</surname>
<given-names>NJ</given-names>
</string-name>, et&#x000a0;al. <article-title>Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers</article-title>. <source>JAMA Neurology</source>. <year>2023</year>;<volume>80</volume>(<issue>4</issue>):<fpage>360</fpage>&#x02010;<lpage>369</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2022.5272</pub-id>
<pub-id pub-id-type="pmid">36745413</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz14537-cit-0026">
<string-name>
<surname>Palmqvist</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tideman</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Cullen</surname>
<given-names>N</given-names>
</string-name>, et&#x000a0;al. <article-title>Prediction of future Alzheimer's disease dementia using plasma phospho&#x02010;tau combined with other accessible measures</article-title>. <source>Nat Med</source>. <year>2021</year>;<volume>27</volume>(<issue>6</issue>):<fpage>1034</fpage>&#x02010;<lpage>1042</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-021-01348-z</pub-id>
<pub-id pub-id-type="pmid">34031605</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz14537-cit-0027">
<string-name>
<surname>Mattsson&#x02010;Carlgren</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Janelidze</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Palmqvist</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Longitudinal plasma p&#x02010;tau217 is increased in early stages of Alzheimer's disease</article-title>. <source>Brain</source>. <year>2021</year>;<volume>143</volume>(<issue>11</issue>):<fpage>3234</fpage>&#x02010;<lpage>3241</lpage>. doi:<pub-id pub-id-type="doi">10.1093/BRAIN/AWAA286</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz14537-cit-0028">
<string-name>
<surname>Jonaitis</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Janelidze</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cody</surname>
<given-names>KA</given-names>
</string-name>, et&#x000a0;al. <article-title>Plasma phosphorylated tau 217 in preclinical Alzheimer's disease</article-title>. <source>Brain Commun</source>. <year>2023</year>;<volume>5</volume>(<issue>2</issue>):<elocation-id>fcad057</elocation-id>. doi:<pub-id pub-id-type="doi">10.1093/braincomms/fcad057</pub-id>
<pub-id pub-id-type="pmid">37013174</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz14537-cit-0029">
<string-name>
<surname>Dor&#x000e9;</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Doecke</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Saad</surname>
<given-names>ZS</given-names>
</string-name>, et&#x000a0;al. <article-title>Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum</article-title>. <source>Alzheimers Dement</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<elocation-id>e12307</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/dad2.12307</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz14537-cit-0030">
<string-name>
<surname>Rissman</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Langford</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Raman</surname>
<given-names>R</given-names>
</string-name>, et&#x000a0;al. <article-title>Plasma A&#x003b2;42/A&#x003b2;40 and phospho&#x02010;tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>2</issue>):<fpage>1214</fpage>&#x02010;<lpage>1224</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13542</pub-id>
<pub-id pub-id-type="pmid">37932961</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz14537-cit-0031">
<string-name>
<surname>Barth&#x000e9;lemy</surname>
<given-names>NR</given-names>
</string-name>, <string-name>
<surname>Salvad&#x000f3;</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Schindler</surname>
<given-names>SE</given-names>
</string-name>, et&#x000a0;al. <article-title>Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests</article-title>. <source>Nat Med</source>. <year>2024</year>;<volume>30</volume>(<issue>4</issue>):<fpage>1085</fpage>&#x02010;<lpage>1095</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-024-02869-z</pub-id>
<pub-id pub-id-type="pmid">38382645</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz14537-cit-0032">
<string-name>
<surname>Janelidze</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Berron</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>R</given-names>
</string-name>, et&#x000a0;al. <article-title>Associations of plasma phospho&#x02010;tau217 levels with tau positron emission tomography in early Alzheimer disease</article-title>. <source>JAMA Neurol</source>. <year>2021</year>;<volume>78</volume>(<issue>2</issue>):<fpage>149</fpage>&#x02010;<lpage>156</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2020.4201</pub-id>
<pub-id pub-id-type="pmid">33165506</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz14537-cit-0033">
<string-name>
<surname>Janelidze</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Teunissen</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Zetterberg</surname>
<given-names>H</given-names>
</string-name>, et&#x000a0;al. <article-title>Head&#x02010;to&#x02010;Head comparison of 8 plasma amyloid&#x02010;&#x003b2; 42/40 assays in Alzheimer disease</article-title>. <source>JAMA Neurol</source>. <year>2021</year>;<volume>78</volume>(<issue>11</issue>):<fpage>1375</fpage>&#x02010;<lpage>1382</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2021.3180</pub-id>
<pub-id pub-id-type="pmid">34542571</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz14537-cit-0034">
<string-name>
<surname>Mattsson&#x02010;Carlgren</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Janelidze</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bateman</surname>
<given-names>RJ</given-names>
</string-name>, et&#x000a0;al. <article-title>Soluble P&#x02010;tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau</article-title>. <source>EMBO Mol Med</source>. <year>2021</year>;<volume>13</volume>(<issue>6</issue>):<elocation-id>e14022</elocation-id>. doi:<pub-id pub-id-type="doi">10.15252/emmm.202114022</pub-id>
<pub-id pub-id-type="pmid">33949133</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz14537-cit-0035">
<string-name>
<surname>Palmqvist</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Insel</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Stomrud</surname>
<given-names>E</given-names>
</string-name>, et&#x000a0;al. <article-title>Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease</article-title>. <source>EMBO Mol Med</source>. <year>2019</year>;<volume>11</volume>(<issue>12</issue>):<elocation-id>e11170</elocation-id>. doi:<pub-id pub-id-type="doi">10.15252/emmm.201911170</pub-id>
<pub-id pub-id-type="pmid">31709776</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz14537-cit-0036">
<string-name>
<surname>Angevaare</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Vonk</surname>
<given-names>JMJ</given-names>
</string-name>, <string-name>
<surname>Bertola</surname>
<given-names>L</given-names>
</string-name>, et&#x000a0;al. <article-title>Predictors of incident mild cognitive impairment and its course in a diverse community&#x02010;based population</article-title>. <source>Neurology</source>. <year>2022</year>;<volume>98</volume>(<issue>1</issue>):<fpage>e15</fpage>&#x02010;<lpage>e26</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000013017</pub-id>
<pub-id pub-id-type="pmid">34853178</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="alz14537-cit-0037">
<string-name>
<surname>Gauthier</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Reisberg</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Zaudig</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Mild cognitive impairment</article-title>. <source>Lancet</source>. <year>2006</year>;<volume>367</volume>(<issue>9518</issue>):<fpage>1262</fpage>&#x02010;<lpage>1270</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0140-6736(06)68542-5</pub-id>
<pub-id pub-id-type="pmid">16631882</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz14537-cit-0038">
<string-name>
<surname>Tavares&#x02010;J&#x000fa;nior</surname>
<given-names>JWL</given-names>
</string-name>, <string-name>
<surname>de Souza</surname>
<given-names>ACC</given-names>
</string-name>, <string-name>
<surname>Borges</surname>
<given-names>JWP</given-names>
</string-name>, et&#x000a0;al. <article-title>COVID&#x02010;19 associated cognitive impairment: a systematic review</article-title>. <source>Cortex</source>. <year>2022</year>;<volume>152</volume>:<fpage>77</fpage>&#x02010;<lpage>97</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cortex.2022.04.006</pub-id>
<pub-id pub-id-type="pmid">35537236</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="alz14537-cit-0039">
<string-name>
<surname>Mattsson&#x02010;Carlgren</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Palmqvist</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Blennow</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hansson</surname>
<given-names>O</given-names>
</string-name>. <article-title>Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies</article-title>. <source>Nat Commun</source>. <year>2020</year>;<volume>11</volume>(<issue>1</issue>):<fpage>6252</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-020-19957-6</pub-id>
<pub-id pub-id-type="pmid">33288742</pub-id>
</mixed-citation></ref><ref id="alz14537-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz14537-cit-0040">
<string-name>
<surname>Hansson</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Mikulskis</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fagan</surname>
<given-names>AM</given-names>
</string-name>, et&#x000a0;al. <article-title>The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: a review</article-title>. <source>Alzheimers Dement</source>. <year>2018</year>;<volume>14</volume>(<issue>10</issue>):<fpage>1313</fpage>&#x02010;<lpage>1333</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2018.05.008</pub-id>
<pub-id pub-id-type="pmid">29940161</pub-id>
</mixed-citation></ref></ref-list><app-group><app id="alz14537-app-0001" content-type="APPENDIX"><sec id="alz14537-sec-0270"><label>1</label><p>A list of all PREVENT&#x02212;AD collaborators can be found at the following website <ext-link xlink:href="https://preventad.loris.ca/acknowledgements/acknowledgements.php?date" ext-link-type="uri">https://preventad.loris.ca/acknowledgements/acknowledgements.php?date</ext-link>=2024&#x02010;12&#x02010;02&#x00026;authors.</p></sec></app></app-group></back></article>